AUSTIN, Texas / May 02, 2023 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its first quarter ended March 31, 2023, after the market close on May 9, 2023. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information:
Event: | Natera’s First Quarter 2023 Financial Results |
Date: | Tuesday, May 9, 2023 |
Time: | 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: | 1 (888) 770-7321, Domestic |
| 1 (929) 201-7107, International |
Conference ID: | 7684785 |
Webcast: | |
A webcast replay will be available at investor.natera.com. | |
About Natera
Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$237.53 |
| Daily Change: | 6.90 2.99 |
| Daily Volume: | 1,114,714 |
| Market Cap: | US$32.780B |
November 12, 2025 November 06, 2025 October 28, 2025 October 20, 2025 | |

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load